Results 261 to 270 of about 1,006,016 (305)

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen   +13 more
wiley   +1 more source

Is There a Role for Intestinal Ultrasound in Polyp Detection? [PDF]

open access: yesACG Case Rep J
Muralidharan S   +3 more
europepmc   +1 more source

Japanese Consensus Document on NexoBrid<sup>®</sup>, a Burn Eschar Removal Agent. [PDF]

open access: yesEur Burn J
Matsumura H   +6 more
europepmc   +1 more source

Econometric Issues on Pseudo Panel Data

open access: yesEconometric Issues on Pseudo Panel Data
openaire  

Home - About - Disclaimer - Privacy